



**Therapix Biosciences signed investment agreements for a total of approx. NIS 5.6 million**

**The investment agreements include a private placement to investors at NIS 1.05 per share, for a total of approx. NIS 3.3 million. In addition, the investors signed agreements for the exercise of options granted in the context of the Dekel transaction, for approx. NIS 2.3 million.**

Therapix, a company engaged in the development of cannabinoid-based drugs, announces today that it had entered into a series of investment agreements for a total of approx. NIS 5.6 million.

The first series of agreements comprises a number of private placements in the Company, at a total amount of approx. NIS 3.3 million. The investors will invest in the Company at NIS 1.05 per share, reflecting a 24% premium on last Monday's closing price of Therapix's shares on TASE.

In addition, the Company signed an agreement for the exercise of options granted in the context of the Dekel transaction, which was approved in August 2015. The investors will exercise options yielding to the Company approx. NIS 2.3 million.

The Company's Board of Directors recently decided to focus the Company's business strategy on creating and enhancing a portfolio of technologies and assets in the field of cannabinoid-based treatment, further to a number of projects in such sector in which the Company chose to engage in the last few months.

It was further resolved to examine the advancement of a program for the development of a cannabinoid-based medical product for treating Tourette's syndrome.

The choice of Tourette's syndrome, under an orphan drug designation, derives from the Company's decision to engage in the development of cannabinoid-based drugs under accelerated regulatory programs compared with the standard course of drug development.

The development of the new drug is based on the "entourage" effect first published in 1988 by Prof. Raphael Mechoulam. The entourage technology is based on the integration of cannabinoid substances or cannabinoid analogs in existing drugs, with a view to improve treatment of various medical indications. The technology is related to the synergy phenomena in medical treatment achieved by the combination of a number of substances in varied dosages, also allowing a reduction of the drug dosages known to be effective, thus enabling the necessary clinical effectiveness while improving the drug's safety profile.



### **About Therapix**

Therapix Biosciences Ltd., is a biopharmaceutical company focused on identifying and investing in promising technologies in the biopharmaceutical field, while placing an emphasis on technologies that are based on a known biological mechanism which has passed the proof-of-concept phase, and which provide a solution for significant medical needs in the market and involve an investment of up to \$2 million for achieving a material milestone. The Company focuses on the creation and expansion of a portfolio of technologies and assets in the field of treatments based on cannabinoids (active compounds in the cannabis plant), and is currently examining the advancement of research and development programs of a cannabinoid-based medical product for treating Tourette's syndrome (under an orphan drug designation) as well as additional cognitive disorders.